Found 329 Enz. Inhib. hit(s) with all data for entry = 9091 
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with PBS containing 2% BSA...More data for this Ligand-Target Pair
